The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
=== Rebel diplomacy === The far-left guerrilla group Revolutionary Armed Forces of Colombia (FARC), was one of the most powerful and violent groups the Colombian government had to deal with during the Colombian Conflict. They gained such strength and influence that they started to look for mechanisms to help them grow even stronger; in that sense, they developed a "Rebel Diplomacy", understood as a rebel group's conduct of foreign affairs during the development civil war for the purpose of advancing its military and political objectives. This diplomacy was used as their strategy for engaging with various international actors as they sought any type of support during various stages of the conflict. Among these international actors are the governments of other countries, non-governmental organizations (NGOs), and multinational corporations. The guerrilla group made intelligent and strategic use of social networks as a means through which to offer the international public who was witnessing the conflict a vision of their own narrative of the conflict, and to present themselves as a credible and preferable alternative to the Colombian government. To that end, FARC designed a web page and obtained support from press agencies and independent digital media, mostly European. Rebel diplomacy often emerges as a kind of counter-diplomacy aimed at discrediting the State against the insurgent group it is fighting; it is a way of taking the battle to the political arena and waging it at an international scale.
=== Web patterns === In general, the webs of P. phalangioides are loose and horizontal with many irregularities. These webs are often intertwined with webs of other spiders of the same population. They live peacefully unless resources are low at which point the spiders turn to cannibalism.
== Function == Nicotinamide phosphoribosyltransferase (iNAMPT) catalyzes the condensation of phosphoribosyl pyrophosphate with nicotinamide (NAM) to yield nicotinamide mononucleotide (NMN) and pyrophosphate (PPi). This is the first step in the biosynthesis of nicotinamide adenine dinucleotide (NAD+). This reaction allows a salvage pathway, in which NAM is recycled from enzymes that use NAD+ (sirtuins, PARPs, CD38) as these produce NAM as a waste product. Thus this reaction is a major source of NAD+ production in the body. De novo synthesis of NAD+ from tryptophan occurs only in the liver and kidney, overwhelmingly in the liver.
=== India === In India, the number of individuals affected by osteoarthritis has increased from 23.46 million in 1990 to 62.35 million in 2019. Knee osteoarthritis was the most prevalent type of osteoarthritis, followed by hand osteoarthritis. In 2019, osteoarthritis was the 20th most common cause of years lived with disability (YLDs) in India, accounting for 1.48% of all YLDs, which increased from 1.25% and 23rd most common cause in 1990.
=== In-situ === In-situ events are the weakest and often most short lived out of CAD event types. These events occur during the absence of ideal synoptic conditions, when the anticyclone position is highly unfavorable located well offshore. In some in situ cases, the barrier pressure gradient is largely due to a cyclone to the southwest rather than the anticyclone to the northeast. Diabatic processes lead to the stabilization of an air mass approaching the Appalachians. Diabatic processes are essential for in-situ events. These events often lead to weak, narrow damming.
Sources: en.wikipedia.org
At the end of 2014, there were almost 571,000 non-German citizens in Lower Saxony. At the end of 2023, there were almost 1,085,315 non-German citizens in Lower Saxony. The highest share of migrants to Germans in Lower Saxony is in the urban agglomeration of Braunschweig (44.8%) which consists the most populated parts of Salzgitter e.g Lebenstedt or Thiede, the town Wolfenbüttel, parts of the districts Landkreis Peine, Landkreis Gifhorn, Landkreis Helmstedt and Landkreis Wolfenbüttel. 57.5% of Salzgitter have a migration background, which has the highest percentage of people with a foreign background in Lower Saxony. The following table illustrates the largest minority groups in Lower Saxony:
It is thought that high glucagon levels and lack of insulin production are the main triggers for the metabolic issues associated with Type I diabetes, in particular maintaining normal blood glucose levels, formation of ketone bodies, and formation of urea. One finding of note is that the glucagon response to hypoglycemia is completely absent in patients with Type I diabetes. Consistently high glucagon concentrations in the blood can lead to diabetic ketoacidosis, which is when ketones from lipid breakdown build up in the blood, which can lead to dangerously low blood glucose levels, low potassium levels, and in extreme cases cerebral edema. It has been proposed that the reason for the high levels of glucagon found in the plasma of patients with Type I diabetes is the absence of beta cells producing insulin and the reciprocal effect this has on delta cells and the secretion of somatostatin.
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
=== PPAR-delta agonists === PPARδ (delta) is the main target of a research chemical named GW501516. It has been shown that agonism of PPARδ changes the body's fuel preference from glucose to lipids. In August 2024, seladelpar became the first PPARδ agonist to be approved for clinical use.
Sources: en.wikipedia.org
=== Alternative medicine === Some alternative practitioners believe EDTA acts as an antioxidant, preventing free radicals from injuring blood vessel walls, therefore reducing atherosclerosis. These ideas are unsupported by scientific studies, and seem to contradict some currently accepted principles. The U.S. FDA has not approved it for the treatment of atherosclerosis.
A ligand is a molecule utilized for cell-signaling that binds to a target tissue for cellular communication. There are many different types of ligands, including internal receptors, cell surface receptors, ion channel receptors, G protein-coupled receptors (GPCRs), and enzyme-linked receptors. Ligands can be divided into two categories, agonists or antagonists. Agonists behave similarly to natural ligands, while antagonists are inhibitors and block the binding of the natural ligand. There are many different subtypes of agonists, including endogenous agonists, super agonist, full agonist, inverse agonist, and irreversible agonist. Radioligands are made up of the radioisotope, linker, and ligand. This structure allows the compound to identify and bind to the target tissue while retaining the ability to be tracked and imaged clinically. When a radioligand binds to its target, it alters the microenvironment of the receptor and surrounding tissue, partially due to the structure of the radioligand itself. Without both the high affinity ligand and the radioisotope, the efficiency of this process is lost.
Banting stated that the reporter had betrayed his confidence, but did not retract his statement and reaffirmed that HBC was responsible for the death of indigenous residents by supplying the wrong kind of food and introducing diseases into the Arctic. As A. Y. Jackson notes in his memoir, since neither the governor nor the general manager had been to the Arctic, the meeting ended with them asking Banting's advice on what HBC ought to do: "He gave them some good advice and later he received a card at Christmas with the Governor's best wishes."
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.